remain overweight rate share highlight herein new dermatologist
survey field partner spherix global insight indic
strong initi skyrizi print real deal manag guidanc
may actual prove conserv given feedback rais
estim turn increas price target
step back continu expect upsid skyrizi newli approv
rinvoq upadacitinib help chang narr name goe
limit accord new survey high volum dermatologist
collect manag patient field partner spherix global
insight skyrizi uptak strong gate anticip acceler
specif end doc indic skyrizi share patient
manag number growth perspect
would put skyrizi share neighborhood psoriasi mainstay enbrel
tremfya even taltz
feedback bullish matter doc ask wherea share project
repres top-down way assess skyrizi use bottom-up practice-specif
approach yield similar result week launch derm alreadi
prescrib skyrizi averag patient project initi next
month prescrib breadth expect tripl next month
near-term prescrib expect fairli aggress
skyrizi use expect initi next quarter translat
increas skyrizi patient
humira impact bad fear though previous express concern
skyrizi cannib humira derm indic like risk
inde tremfya stelara ilumya select derm
respect deem like replac skyrizi versu humira
model implic meaning rais skyrizi estim
readi model feedback verbatim think worth note patient share
previous model roughli annual run-rat given
given appear well-manag access process feedback indic
pa approv rate rais ww skyrizi number
number meaning ahead guidanc consensu
bottom line remain confid thesi effect chang
narr toward one growth skyrizi rinvoq launch play
commerci regulatori clinic ip risk associ market pipelin product
fulli integr biopharmaceut compani
ep discount back
year
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
remain overweight rate share highlight herein new dermatologist survey
field partner spherix global insight indic strong initi
skyrizi print real deal manag guidanc may actual
prove conserv given feedback rais estim
step back continu expect upsid skyrizi newli approv rinvoq
upadacitinib help chang narr name goe offens
commerci describ detail target share increas
remain buyer
note highlight new survey data partner spherix global insight
survey field may meant gaug percept use pattern
project high-volum us dermatologist relat psoriasi elig
particip survey dermatologist practic two year
manag least pso patient treat least pso patient biolog agent spend
least half profession time clinic practic see patient spend least
profession time medic oppos cosmet dermatolog collect sampl
dermatologist treat pso patient moderate/sever us adult
psoriasi popul estim
close survey dermatologist awar skyrizi approv roughli one-
month post-launch exhibit similar percentag indic familiar
skyrizi improv prior three month indic learn littl
indic learn consider skyrizi least
like attribut market prowess
awar new inform skyrizi past three month
spherix
question familiar skyrizi treatment pso chang past three month
awar fda approv skyrizi treatment pso
page
top-
perspect
time survey field skyrizi share ask top-down perspect
project skyrizi market share doc estim captur fulli pso market within
next six month see exhibit would put skyrizi close tremfya whose share
project remain flat would make skyrizi share doubl ilumya project
reach share six month note consist feedback spherix
survey derm project skyrizi would reach market share within six month
contrast skyrizi project market share gain mani biolog project see
share eros come six month includ humira project lose share
declin stelara project lose share declin
lesser extent enbrel cosentyx
current futur brand share among biolog treat patient
question consid pso patient biolog pleas alloc percent patient follow brand total equal
month pso patient treat biolog anticip brand alloc refer current brand usag provid
consid pso patient current treat biolog percent fall follow categori
page
well
corrobor skyrizi market share project shown exhibit think valuabl
examin dermatologist use project use patient-numb estim among current futur
skyrizi prescrib walk importantli exercis yield skyrizi growth
assumpt larg consist market share project describ previous
week post-launch survey dermatologist alreadi start
patient skyrizi prescrib averag patient drug exhibit
multipli indic survey derm total pso patient
skyrizi
current skyrizi prescrib intend prescrib skyrizi next three month fact
expect new initi acceler compar project averag new
initi next three month exhibit indic current prescrib expect
add skyrizi patient next three month
assum discontinu among patient alreadi initi would impli
current prescrib skyrizi patient
skyrizi uptak current user averag patient skyrizi
question indic biologic-tr pso patient skyrizi exactli mani pso patient
page
current user anticip skyrizi initi month
question indic biologic-tr pso patient skyrizi exactli mani pso patient
skyrizi growth expect come increas prescrib breadth close one-fifth
survey dermatologist expect start prescrib skyrizi within next month
anoth expect start prescrib within next month hold
true skyrizi prescrib breadth increas end
current non-us expect start prescrib skyrizi next month plan
fairli aggress adopt indic initi averag patient time
simpl math indic new prescrib expect start
patient skyrizi within next month
timelin skyrizi trial current non-us
question anticip prescrib skyrizi pso patient mani patient plan initi skyrizi
next three month
page
current prescrib averag skyrizi patient current patient
current prescrib expect skyrizi initi next initi
near-term prescrib expect skyrizi initi next initi
thu dermatologist expect number skyrizi-tr patient increas
next three month roughli increas note lower
increas suggest market share project refer exhibit
differ may due round current share project increas
would repres increas skyrizi use triangul project skyrizi use trend
use bottom-up approach accord current project patient initi among
exist near-term prescrib give us increas confid market share project
feedback sum point sharp near-term increas skyrizi use
appear secur fairli broad access skyrizi alreadi small feat
especi consid access prove barrier adopt year launch
mani biolog aspect skyrizi launch believ bode well near-term
revenu number among skyrizi user classifi speed eas manag
care approv slow difficult major respond requir provid prior
author manag care approv exhibit experienc good track record
pa approv time survey field close pa approv pend
deni common requir manag care approv proof
prior failur system agent proof prior failur tnf mandatori use
specialti pharmaci rel fewer derm indic proof prior failur anti-il-
agent otezla requir none requir proof failur anoth
skyrizi access
requir manag approv skyrizi
question follow requir manag care approv skyrizi select appli prior author complet skyrizi
percent fall follow categori indic prior author deni best knowledg pleas explain patient deni
page
skyrizi may less
threat humira
initi
previous highlight concern humira cannib skyrizi see prior note
previou discuss note howev derm ask biolog agent
like displac skyrizi select tremfya stelara ilumya ahead humira
exhibit fact respond indic humira agent like
replac skyrizi anoth indic none like go replac skyrizi
suggest pso biolog market continu expand approv skyrizi
exactli surpris skyrizi pose bigger threat approv
agent particularli given conveni dose profil fact market
physician hold high esteem support share project exhibit
indic tremfya share remain flat next six month ilumya growth
point derm temper expect humira eros
spherix survey doc project humira share would fall six month follow
skyrizi approv half declin would attribut
skyrizi avail scenario franchis whole project lose
share psoriasi market within first six month skyrizi avail feedback
suggest abbv pso market dynam play quit project
derm project humira share loss skyrizi share gain next six
month net gain pso share exhibit coupl feedback exhibit
indic us skyrizi impact humira may bad initi fear
agent like replac skyrizi
question product list agent skyrizi like replac practic pleas select one ask familiar skyrizi
page
given view extrem posit feedback skyrizi term market share
project access grow prescrib breadth depth rais revenu
estim us lesser extent ex-u
note six month share project put skyrizi share six month wherea
previous model skyrizi achiev us market share physician notori
overestim magnitud market share chang six-month project
plug feedback verbatim model assum us skyrizi psoriasi share
previou estim respect
ww skyrizi revenu estim come repres upsid
manag guidanc consensu likewis estim
increas consider ahead consensu view
achiev base survey feedback
pjc consensu skyrizi non-gaap ep estim
chang skyrizi revenu estim bump non-gaap ep estim
continu deriv price target share appli
multipl ep estim discount back target move
previous increas ep estim laps partial
page
skyrizi revenu pjc prior skyrizi current skyrizi skyrizi epspjc prior non-gaap ep current non-gaap ep non-gaap ep estim assum merger complet unclear includ consensu ep estimate factset skyrizi consensu includ estim estim rang piper jaffray co
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
